Advertisement

Für Sie gelesen: Internationale Fachliteratur

  • Springer, Berlin
Chapter

Zusammenfassung

Die weltweite Zunahme von Malariastämmen, die gegen die gebräuchlichsten Anti-Malaria-Medikamente resistent sind, hat in den betroffenen Regionen einen Wiederanstieg der Malariabedingten Sterblichkeit zur Folge. Am Beispiel der Entwicklung der Sterblichkeit in drei Regionen des westafrikanischen Senegals über den Zeitraum der vergangenen elf Jahre, während derer sich in diesen Regionen die Resistenz gegen Chloroquin ausbreitete, konnten Trape et al. [1] nachweisen, daß parallel zur Resistenzausbreitung die Malariabedingte Sterblichkeit je nach Region um das zwei- bis achtfache zunahm.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Trape JF, Pison G, Preziosi MP et al. (1998) Impact of chloroquine resistance on malaria mortality. C R Acad Sci Paris Serie III 321:689–697.Google Scholar
  2. WHO: Health in Europe 1997 www.who.int/
  3. Galimand M, Gerbaud G, Guibourdenche M, Riou J-Y, Courvalin P (1998) High-level chloramphenicol resistance in Neisseria meningitidis. N Eng JMed 339:868–874.CrossRefGoogle Scholar
  4. Meningitis B vaccine looks promising. (1998) [News] BMJ 317:770.Google Scholar
  5. Björkman J, Hughes D, Anderson DI (1998) Virulence of antibiotic-resistant Salmonella typhimurium. Proc Natl Acad Sci USA 95:3949–3953.PubMedCrossRefGoogle Scholar
  6. Wainberg MA, Friedland G (1998) Public Health implications of antiretroviral therapy and HIV drug resistance. JAMA 279:1977–1983.PubMedCrossRefGoogle Scholar
  7. Research News (1998) Versatile gene uptake system found in Cholera bacterium. Science 280:521–522.CrossRefGoogle Scholar
  8. Takala AK, Koskenniemi E, Joensuu J, Mäkelä M, Vesikari T (1998) Economic evaluation of rotavirus vaccinations in Finland: randomized, double-blind, placebo-controlled trial of tetravalent rhesus rotavirus vaccine. Clin Inf Dis 27:272–282.CrossRefGoogle Scholar
  9. Balaban N, Goldkom T, Nhan RT et al (1998) Autoinducer of virulence as a target for vaccine and therapy against Staphylococcus aureus. Science 280:438–440.PubMedCrossRefGoogle Scholar
  10. Pablos-Méndez A, Raviglione MC, Laszlo A et al. (1998) Global surveillance for antituberculosis-drug resistance, 1994–1997. N Eng J Med 338:1641–1649.CrossRefGoogle Scholar
  11. Heymann SJ, Sell R, Brewer TF (1998) The influence of program acceptability on the effectiveness of public health policy: a study of directly observed therapy fort tuberculosis. Am J Public Health 88:442–445.PubMedCrossRefGoogle Scholar
  12. Zwarenstein M, Schoemann JH, Vundule C, Lombard CJ, Tatley M (1998) Randomised controlled trial of self-supervised and directly observed treatment of tuberculosis. Lancet 352:1340–1343.PubMedCrossRefGoogle Scholar
  13. Ghani AC, Ferguson NM, Donnelly CA, Hagenaars TJ, Anderson RM (1998) Estimation of the number of people incubating variant CJD. Lancet 352:1353–1354.PubMedCrossRefGoogle Scholar
  14. CDC (1998) Hepatitis A vaccination of men who have sex with men — Atlanta, Georgia, 1996–1997. MMWR 47: 708–711.Google Scholar
  15. Herbein G, Mahlknecht U, Batliwalla F, Gregersen P et al. (1998) Apoptosis of CD8+ T cells is mediated by macrophages through interaction of HIV gp 120 with chemokine receptor CXCR4. Nature 395:189–194.PubMedCrossRefGoogle Scholar
  16. Sullivan BL, Takefman DM, Spear GT (1998) Complement can neutralize HIV-1 plasma virus by a C5-independent mechanism. Virology 248:173–181.PubMedCrossRefGoogle Scholar
  17. Storey A, Thomas M, Kalita A, Harwood C et al. (1998) Role of a p53 polymorphism in the development of human papilloma-virusassociated cancer. Nature 393:229–234.PubMedCrossRefGoogle Scholar
  18. zur Hausen H (1998) Papillomavirus and p53. Nature 393:217.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1999

Authors and Affiliations

  • Springer, Berlin

There are no affiliations available

Personalised recommendations